Pentoxifylline does not improve outcome in a murine model for the multiple-organ dysfunction syndrome

Intensive Care Medicine

Volumn 31, Issue 5, 2005, Pages 701-708

  Volman, T J H ^a   Goris, R J A ^a   Hendriks, T ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cytokines; Mice; Multiple organ failure; Pentoxifylline; Zymosan

Indexed keywords

INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MESSENGER RNA; PENTOXIFYLLINE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY TEMPERATURE; BODY WEIGHT; CONTROLLED STUDY; DRUG EFFECT; KIDNEY; LIVER; LUNG; LUNG INJURY; MACROPHAGE; MORTALITY; MOUSE; MULTIPLE ORGAN FAILURE; NONHUMAN; ORGAN WEIGHT; PROTEIN BLOOD LEVEL; SPLEEN; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TREATMENT OUTCOME;

ANIMALS; CELLS, CULTURED; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; MICE; MICE, INBRED C57BL; MULTIPLE ORGAN FAILURE; PENTOXIFYLLINE; RANDOM ALLOCATION; SURVIVAL ANALYSIS; VASODILATOR AGENTS; ZYMOSAN;

EID: 18844362434     PISSN: 03424642     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00134-005-2570-z     Document Type: Article

References (41)

1. Seely AJ, Christou NV (2000) Multiple organ dysfunction syndrome: exploring the paradigm of complex nonlinear systems. Crit Care Med 28:2193-2200
2. Marshall JC (2001) Inflammation, coagulopathy, and the pathogenesis of multiple organ dysfunction syndrome. Crit Care Med 29:S99-S106
3. Goris RJ, Boekholtz WK, van Bebber IP, Nuytinck JK, Schillings PH (1986) Multiple-organ failure and sepsis without bacteria. An experimental model. Arch Surg 121:897-901
4. Goris RJ (1996) MODS/SIRS: result of an overwhelming inflammatory response? World J Surg 20:418-421
5. Jansen MJ, Hendriks T, Verhofstad AA, Lange W, Geeraedts-LM J, Goris RJ (1997) Gradual development of organ damage in the murine zymosan-induced multiple organ dysfunction syndrome. Shock 8:261-267
6. Volman TJH, Goris RJ, van der Jagt M, van de Loo FAJ, Hendriks T (2002) Organ damage in zymosan-induced multiple organ dysfunction syndrome in mice is not mediated by inducible nitric oxide synthase. Crit Care Med 30:1553-1559
7. Demling R, Lalonde C, Youn YK, Daryani R, Campbell C, Knox J (1992) Lung oxidant changes after zymosan peritonitis: relationship between physiologic and biochemical changes. Am Rev Respir Dis 146:1272-1278
8. Shayevitz JR, Miller C, Johnson KJ, Rodriguez JL (1995) Multiple organ dysfunction syndrome: end organ and systemic inflammatory response in a mouse model of nonseptic origin. Shock 4:389-396
9. Cuzzocrea S, McDonald MC, Mazzon E, Filipe HM, Centorrino T, Lepore V, Terranova ML, Ciccolo A, Caputi AP, Thiemermann C (2001) Beneficial effects of tempol, a membrane-permeable radical scavenger, on the multiple organ failure induced by zymosan in the rat. Crit Care Med 29:102-111
10. Jansen MJ, Hendriks T, Vogels MT, Van der Meer JW, Goris RJ (1996) Inflammatory cytokines in an experimental model for the multiple organ dysfunction syndrome. Crit Care Med 24:1196-1202
11. Volman TJ, Goris RJ, Van der Meer JW, Hendriks T (2004) Tissue- and time-dependent upregulation of cytokine mRNA in a murine model for the multiple organ dysfunction syndrome. Ann Surg 240:142-150
12. Jansen MJ, Hendriks T, Knapen MF, van Kempen LC, Van der Meer JW, Goris RJ (1998) Chlorpromazine downregulates tumor necrosis factor-alpha and attenuates experimental multiple organ dysfunction syndrome in mice. Crit Care Med 26:1244-1250
13. Jansen MJ, Hendriks T, Hermsen R, Van der Meer JW, Goris RJ (1998) A monoclonal antibody against tumour necrosis factor-alpha improves survival in experimental multiple organ dysfunction syndrome. Cytokine 10:904-910
14. Jansen MJ, Hendriks T, de Man BM, Van der Meer JW, Goris RJ (1999) Interleukin 10 mitigates the development of the zymosan-induced multiple organ dysfunction syndrome in mice. Cytokine 11:713-721
15. Dettelbach HR, Aviado DM (1985) Clinical pharmacology of pentoxifylline with special reference to its hemorrheologic effect for the treatment of intermittent claudication. J Clin Pharmacol 25:8-26
16. Ward A, Clissold SP (1987) Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs 34:50-97
17. Lundblad R, Ekstrom P, Giercksky KE (1995) Pentoxifylline improves survival and reduces tumor necrosis factor, interleukin-6, and endothelin-1 in fulminant intra-abdominal sepsis in rats. Shock 3:210-215
18. Koo DJ, Yoo P, Cioffi WG, Bland KI, Chaudry IH, Wang P (2000) Mechanism of the beneficial effects of pentoxifylline during sepsis: maintenance of adrenomedullin responsiveness and downregulation of proinflammatory cytokines. J Surg Res 91:70-76
19. Tong Z, Chen B, Dai H, Bauer PC, Guzman J, Costabel U (2004) Extrinsic allergic alveolitis: inhibitory effects of pentoxifylline on cytokine production by alveolar macrophages. Ann Allergy Asthma Immunol 92:234-239
20. Doherty GM, Jensen JC, Alexander HR, Buresh CM, Norton JA (1991) Pentoxifylline suppression of tumor necrosis factor gene transcription. Surgery 110:192-198
21. Bahra PS, Rainger GE, Wautier JL, Nash GB (2001) Effects of pentoxifylline on the different steps during adhesion and transendothelial migration of flowing neutrophils. Cell Biochem Funct 19:249-257
22. Tighe D, Moss R, Hynd J, Boghossian S, al Saady N, Heath MF, Bennett ED (1990) Pretreatment with pentoxifylline improves the hemodynamic and histologic changes and decreases neutrophil adhesiveness in a pig fecal peritonitis model. Crit Care Med 18:184-189
23. Sullivan GW, Carper HT, Novick WJJ, Mandell GL (1988) Inhibition of the inflammatory action of interleukin-1 and tumor necrosis factor (alpha) on neutrophil function by pentoxifylline. Infect Immun 56:1722-1729
24. Beshay E, Croze F, Prud'homme GJ (2001) The phosphodiesterase inhibitors pentoxifylline and rolipram suppress macrophage activation and nitric oxide production in vitro and in vivo. Clin Immunol 98:272-279
25. Volman TJH, Hendriks T, Verhofstad AA, Kullberg BJ, Goris RJ (2002) Improved survival of TNF-deficient mice during the zymosan-induced multiple organ dysfunction syndrome. Shock 17:468-472
26. Chomczynski P, Sacchi N (1987) Single-step method of RNA isolation by acid guanidinium thiocyanate-phenolchloroform extraction. Anal Biochem 162:156-159
27. Bone RC (1996) Toward a theory regarding the pathogenesis of the systemic inflammatory response syndrome: what we do and do not know about cytokine regulation. Crit Care Med 24:163-172
28. Malazdrewich C, Thumbikat P, Abrahamsen MS, Maheswaran SK (2004) Pharmacological inhibition of Mannheimia haemolytica lipopolysaccharide and leukotoxin-induced cytokine expression in bovine alveolar macrophages. Microb Pathog 36:159-169
29. Poulakis N, Androutsos G, Kazi D, Bastas A, Provata A, Bitsakou C, Kontozoglou T, Polyzogopoulou C, Tassiopoulou A (1999) The differential effect of pentoxifylline on cytokine production by alveolar macrophages and its clinical implications. Respir Med 93:52-57
30. Myers MJ, Baarsch MJ, Murtaugh MP (2002) Effects of pentoxifylline on inflammatory cytokine expression and acute pleuropneumonia in swine. Immunobiology 205:17-34
31. Tong Z, Dai H, Chen B, Abdoh Z, Guzman J, Costabel U (2003) Inhibition of cytokine release from alveolar macrophages in pulmonary sarcoidosis by pentoxifylline: comparison with dexamethasone. Chest 124:1526-1532
32. Honess DJ, Dennis IF, Bleehen NM (1993) Pentoxifylline: its pharmacokinetics and ability to improve tumour perfusion and radiosensitivity in mice. Radiother Oncol 28:208-218
33. Miller K, Louie A, Baltch AL, Smith RP, Davis PJ, Gordon MA (1998) Pharmacokinetics of pentoxifylline and its metabolites in healthy mice and in mice infected with Candida albicans. Antimicrob Agents Chemother 42:2405-2409
34. DeVault GAJ, Kohan DE, Nelson EW, Holman JMJ (1994) The effects of oral pentoxifylline on the cytokine release syndrome during inductive OKT3. Transplantation 57:532-540
35. Kremsner PG, Grundmann H, Neifer S, Sliwa K, Sahlmuller G, Hegenscheid B, Bienzle U (1991) Pentoxifylline prevents murine cerebral malaria. J Infect Dis 164:605-608
36. Edwards MJ, Heniford BT, Klar EA, Doak KW, Miller FN (1992) Pentoxifylline inhibits interleukin-2-induced toxicity in C57BL/6 mice but preserves antitumor efficacy. J Clin Invest 90:637-641
37. Louie A, Baltch AL, Franke MA, Ritz WJ, Smith RP, Singh JK, Gordon MA (1996) Effect of pentoxifylline on the course of systemic Candida albicans infection in mice. J Antimicrob Chemother 37:943-954
38. Diaz Granados N, Howe K, Lu J, McKay DM (2000) Dextran sulfate sodium-induced colonic histopathology, but not altered epithelial ion transport, is reduced by inhibition of phosphodiesterase activity. Am J Pathol 156:2169-2177
39. Sha MC, Callahan CM (2003) The efficacy of pentoxifylline in the treatment of vascular dementia: a systematic review. Alzheimer Dis Assoc Disord 17:46-54
40. Hoffmann H, Markewitz A, Kreuzer E, Reichert K, Jochum M, Faist E (1998) Pentoxifylline decreases the incidence of multiple organ failure in patients after major cardio-thoracic surgery. Shock 9:235-240
41. Staubach KH, Schroder J, Stuber F, Gehrke K, Traumann E, Zabel P (1998) Effect of pentoxifylline in severe sepsis: results of a randomized, double-blind, placebo-controlled study. Arch Surg 133:94-100